Drug Profile
Macuneos - Biophytis
Alternative Names: BIO-201Latest Information Update: 03 Jan 2024
Price :
$50
*
At a glance
- Originator Biophytis
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Age-related macular degeneration
- Preclinical Dry age-related macular degeneration; Stargardt disease
Most Recent Events
- 03 Jan 2024 Macuneos is still in preclinical development for Stargardt disease in France (PO) (Biophytis pipeline, January 2024)
- 03 Jan 2024 Macuneos is still in phase-I development for Age-related-macular-degeneration (In the elderly, In volunteers) in France (PO) (Biophytis pipeline, January 2024)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Stargardt disease in France (PO)